Meeting
2019 Genitourinary Cancers Symposium
Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Authors
Andrew J. Armstrong
Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, NC
Andrew J. Armstrong , Russell Zelig Szmulewitz , Daniel Peter Petrylak , Arnauld Villers , Arun Azad , Antonio Alcaraz , Boris Y. Alekseev , Taro Iguchi , Neal D. Shore , Brad Rosbrook , Jennifer Sugg , Benoit Baron , Lucy F. Chen , Arnulf Stenzl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02677896
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 687)
DOI
10.1200/JCO.2019.37.7_suppl.687
Abstract #
687
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![The association of germline<em> HSD3B1</em> genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].](https://d201v5jt9ylckg.cloudfront.net/288/14370/212152/212152_A1803_poster_pv.jpg)
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
First Author: Nima Sharifi
Poster
2023 ASCO Genitourinary Cancers Symposium
Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).
First Author: Neal D. Shore
Poster
2022 ASCO Annual Meeting
Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
First Author: Andrew J. Armstrong
Poster
2022 ASCO Annual Meeting
Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
First Author: Neal D. Shore